BBIBP-CorV疫苗在波黑联邦60岁及以上人群中针对COVID-19的疫苗有效性:Delta优势期的检测阴性病例对照研究
在波黑联邦11个初级卫生保健中心开展的检测阴性病例对照研究,纳入1711名60岁及以上参与者(933例病例、778例对照),评估BBIBP-CorV全程基础免疫对COVID-19的疫苗有效性。结果显示对轻症无有效性,对中重度COVID-19总体有效性为65.0%(95%CI:40.1-79.5),接种后<90天有效性最高为78.7%(95%CI:54.8-89.9),此后点估计值下降。
要点
- 两剂BBIBP-CorV对60岁及以上人群中重度COVID-19有相当保护作用。
- 对轻症COVID-19未观察到有效性。
- 接种后<90天有效性最高,此后点估计值下降,提示可能需要额外剂量。
核心结论
- 两剂BBIBP-CorV在Delta优势期对老年人中重度COVID-19提供相当保护,接种后3个月内有效性最高,此后点估计值下降,提示需要额外剂量。
研究设计与样本
- 检测阴性病例对照研究,监测点为11个初级卫生保健中心,回顾性按共同方案收集2021年10月1日至2022年1月4日患者数据。
- 共纳入1711名60岁及以上参与者,其中病例933例、对照778例。
主要发现
- 933例病例中508例(54.4%)为轻症,425例(45.6%)为中重度表现。
- 对轻症COVID-19未观察到有效性。
- 对中重度COVID-19总体疫苗有效性为65.0%(95%CI:40.1-79.5)。
- 末剂接种至发病间隔<90天者疫苗有效性为78.7%(95%CI:54.8-89.9),90-119天者为66.0%(95%CI:-0.5-88.5),120-149天者为42.1%(95%CI:-88.6-82.3),≥150天者为45.0%(95%CI:-94.0-84.4)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COVID-19 vaccine uptake in the Federation of Bosnia and Herzegovina (FBiH) accelerated in the second half of 2021, with greater vaccine availability. In this study, we estimated the vaccine effectiveness (VE) of complete primary series BBIBP-CorV vaccine against COVID-19 in patients aged 60 years and older, during the Delta-dominant period, using a test-negative case-control design. Surveillance sites were 11 primary health care centers (PHC) collecting patient data from October 1, 2021, to January 4, 2022, retrospectively according to a common protocol. In total, we included 1711 participants in the analysis: 933 cases and 778 controls. Of the 933 cases, 508 (54.4 %) had mild and 425 (45.6 %) had moderate to severe disease presentation. We observed no effectiveness against mild COVID-19. Overall vaccine effectiveness was 65.0 % (95 %CI: 40.1-79.5) against moderate to severe COVID-19. In time since vaccination analysis, VE was 78.7 % (95 % CI: 54.8-89.9) in patients who received their last dose < 90 days before onset; 66.0 % (95 % CI: -0.5-88.5) in those 90-119 days before onset; 42.1 % (95 % CI: -88.6-82.3) in those 120-149 days before onset and 45.0 % (95 % CI: -94.0-84.4) in those ≥ 150 days before onset. In our study, two doses of BBIBP-CorV provided considerable protection against moderate to severe COVID-19 in older adults, highest within 3 months after second dose, during the Delta-dominant period. Point estimates declined thereafter, suggesting a need for additional doses.
引用
- Musa S, Merdrignac L, Skocibusic S, et al. BBIBP-CorV vaccine effectiveness against COVID-19 in patients aged 60 years and older during the Delta-dominant period in the Federation of Bosnia and Herzegovina, a test-negative case-control study. Vaccine. 2024. PMID: 38644077. doi:10.1016/j.vaccine.2024.04.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。